Aardvark Expects To Update On Paused Phase 3 Trial Of ARD-101 In Q2 2026; FY25 Net Loss Widens

AI Briefing

• – Aardvark Therapeutics reports widening FY25 net loss
• – Company to update on paused Phase 3 trial of ARD-101 in Q2 2026
• – Aardvark Therapeutics fourth-quarter and full-year 2025 financial results